Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramlintide+Metreleptin in Obese Subjects
NCT01235741Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Jan 2011
- Primary completion
- Sep 2011
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pramlintide, metreleptin in obesity, sponsored by AstraZeneca. Started Jan 2011; status: terminated.
02
Drugs
pramlintidemetreleptin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT01235741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01235741.